Market Overview

Dawson James Securities Reiterates Market Outperform Rating, $4 PT on Keryx Biopharmaceuticals

Related KERX
Infoblox Inc Gains On Upbeat Results; The Gap Inc. Shares Decline
H.C. Wainwright & Co. Believes Keryx Biopharmaceuticals Remains Undervalued

In a report published Wednesday, Dawson James Securities reiterated its Market Outperform rating and $4.00 price target on Keryx Biopharmaceuticals (NASDAQ: KERX).

Dawson James Securities noted, “We maintain our Market Outperform rating and $4 price target on KERX shares. We derive our $4 price target by the synthesis of our DCF valuation ($3.73), comparables analysis (~$5.00), and our standardized CAGR methodology ($5.77). Risks to our valuation included clinical and regulatory, partnering, competitive, reimbursement, intellectual property and financial.”

Keryx Biopharmaceuticals closed on Tuesday at $2.93.

Latest Ratings for KERX

DateFirmActionFromTo
Aug 2014FBR CapitalInitiates Coverage onMarket Perform
Mar 2014Mizuho SecuritiesInitiates Coverage onBuy
Mar 2014Stifel NicolausMaintainsBuy

View More Analyst Ratings for KERX
View the Latest Analyst Ratings

Posted-In: Dawson James SecuritiesAnalyst Color Reiteration Analyst Ratings

 

Related Articles (KERX)

Around the Web, We're Loving...

Get Benzinga's Newsletters